Dexcom Expands AID Partnership Into The Netherlands

Rhea-AI Summary

Dexcom, a leader in real-time continuous glucose monitoring (CGM), announced the integration of its Dexcom G6 CGM with the Omnipod® 5 Automated Insulin Delivery (AID) System in the Netherlands. This deployment aims to improve diabetes management for the 100,000 individuals with Type 1 diabetes in the country, including 10,000 children. The system is the first tubeless Hybrid Closed Loop (HCL) approved for children in the Netherlands and promises significant health benefits, including increased time in range (+11.5%) and reduced HbA1c levels. The Dexcom G6 is highly water-resistant and allows remote monitoring via the 'Follow' app, giving users and caregivers more flexibility and peace of mind. The Dexcom G6 is reimbursed by Dutch health insurers for children (18 and under), pregnant women, women trying for pregnancy, and Type 1 hypo unaware users.

Positive

• Integration with Omnipod® 5 provides a more effective diabetes management system.
• Dexcom G6 shows a significant increase in time in range (+11.5%) and reduced HbA1c levels.
• Dexcom G6 is highly water-resistant, enhancing usability in various activities.
• Remote monitoring via the 'Follow' app offers additional safety for users.
• Reimbursement by Dutch health insurers for children, pregnant women, and Type 1 hypo unaware users.

Negative

• to the Netherlands, restricting immediate global impact.

Insights

Medical Research Analyst

Dexcom's expansion into the Netherlands with the Omnipod® 5 Automated Insulin Delivery (AID) System integrated with the Dexcom G6 Continuous Glucose Monitor (CGM) is a significant development in diabetes management. The integration of these technologies can improve glycemic control, leading to enhanced quality of life for individuals with Type 1 diabetes, including children. Studies have shown increased time in range and reduced HbA1c levels, which are important metrics in diabetes care. This hybrid closed-loop system offers greater convenience and accuracy, potentially reducing the burden of daily diabetes management tasks.

Market Research Analyst

The integration of Dexcom G6 with Omnipod® 5 in the Netherlands positions Dexcom as a leader in connected diabetes management solutions. This move could enhance market penetration and increase sales in the European market. The Netherlands has a substantial population of Type 1 diabetes patients and the availability of this advanced system could drive adoption rates. Additionally, the reimbursement by health insurers for children, pregnant women and specific Type 1 users could broaden the customer base and boost revenue streams.

Tech Expert

The technological advancements in the Dexcom G6 and Omnipod® 5 integration emphasize the importance of real-time data sharing and remote monitoring. The unique ‘Follow’ app that allows users to connect and share glucose data with up to 10 followers offers significant value, particularly for parents and caregivers. This feature enhances patient safety and monitoring capabilities, which are essential facets of modern health technology. The water resistance of the on-body parts further adds to the system's practicality and usability.

• The world’s most connected continuous glucose monitoring system^‡, Dexcom G6, now connects with the Omnipod® 5 Automated Insulin Delivery (AID) System in The Netherlands.

EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod^® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier^1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,000 children affected*, making it the most common autoimmune disease among children after asthma ⁴. Type 1 diabetes can be challenging for anyone to manage and live with, but for children with Type 1, and their families, everyday activities such as exercising, eating, and swimming can be even more challenging. The Omnipod^® 5 tubeless insulin pump integrated with the Dexcom G6 CGM can simplify their lives by offering easier^1-2,4 diabetes management whilst allowing families, friends, and carers to remotely check glucose levels with the unique to Dexcom ‘Follow’ app^||.

Research² published in Diabetes Care shows that use of this Hybrid Closed Loop system (HCL) significantly increased time in range (+11.5%) and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with Type 1 diabetes. The same study also saw adult participants spend an additional 11.8% more time in range. These significant and clinically meaningful health outcomes are only proven when the Omnipod^® 5 HCL system is integrated with Dexcom CGM.

Paediatrician Maartje Wijers-van Amelsfort M.D. from the Slingeland hospital in Doetinchem, said: “Thanks to sensors like the Dexcom G6 we can use more and more data to keep track of our patients’ diabetes. The rise of AID helps in that too. We can better monitor and adjust our treatment where necessary. This makes it easier to manage diabetes.”

Unique features give people more flexibility

For adults and children with Type 1 diabetes, this new Dexcom G6 and Omnipod^® 5 hybrid closed loop system, is an important step in improving their diabetes management ^†. The system is the first tubeless HCL in the Netherlands approved for children, offering discretion and freedom to move without concern about tubes snagging or being pulled out. However, perhaps of most interest to parents or caregivers is the, unique to Dexcom, ‘Follow’ app that allows Dexcom CGM users to simultaneously connect to their Omnipod^® 5 pump whilst sharing their glucose data in real time with up to 10 followers, offering everyone a little more peace of mind^||. Moreover, with Dexcom G6^§, the on-body parts of the system have a high-level of water resistance**, so exercising and playing in swimming pools, seas and lakes becomes much easier.

Most connected diabetes sensor

Emphasising Dexcom’s position as a leader in integrating connected systems, Dexcom G6 was exclusively used in the clinical trials that led to the regulatory approval of Omnipod^® 5 in Europe, Canada, and the United States^2,5. Dexcom offers users choice and flexibility when it comes to how they manage their diabetes and view glucose levels. For example, Dexcom CGM also links^# with multiple insulin pumps, digital health apps, lifestyle devices such as Garmin and Apple. All these options give people with diabetes freedom in managing the disease and making the right choice for them when it comes to appropriate care.

Dexcom G6 is available for reimbursement in the Netherlands via health insurers for children (18 and under), pregnant women (Type 1 and Type 2), women trying for pregnancy, and Type 1 hypo unaware users. Those interested in the HCL system should speak to their healthcare provider or visit dexcom.nl for more information.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations in the Netherlands, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

‡ Dexcom Data on File, 2024.
* Netherlands Institute for Healthcare Research & National Institute for Public Health and the Environment, Diabetes Mellitus in the Netherlands 2020, 13
§ The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under up to 2.4m of water for up to 24 hours without failure when properly installed.
** The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller are not waterproof.
†Compared to patients not using an AID system
||Separate Dexcom Follow app and internet connection required. Users should always confirm measurements on the Dexcom [G6 app or receiver before making a treatment decision.
Time in target range was defined as time within a glucose range of 3.9-10.0 mmol/L - 70-180 mg/dL.
#The extensive list of compatible devices can be found at: https://www.dexcom.com/nl-NL/compatibility

1 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 2 Brown SA, et al. Diabetes Care. 2021;44(7):1630-1640. 3 Diabetes Fonds. Diabetes in Numbers. diabetsfonds.nl Accessed June, 2024. https://www.diabetesfonds.nl/over-diabetes/diabetes-in-het-algemeen/diabetes-in-cijfers 4 Sherr, J.L, et al. Diabetes Care 2022; 45(8):1907-1910

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620896482/en/

Dexcom EMEA

Gemma McDonald

+44 (0) 7552 368398

gemma.mcdonald@dexcom.com

Source: DexCom, Inc.

FAQ

What is the recent development involving Dexcom in the Netherlands?

Dexcom announced the integration of its G6 Continuous Glucose Monitor with the Omnipod® 5 Automated Insulin Delivery System in the Netherlands, aiming to improve diabetes management for people with Type 1 diabetes.

How does the Dexcom G6 and Omnipod® 5 system benefit people with diabetes?

The system increases time in range by 11.5%, reduces HbA1c levels, and offers remote monitoring capability through the 'Follow' app, providing significant health benefits and peace of mind.

Who qualifies for reimbursement of the Dexcom G6 in the Netherlands?

Reimbursement is available for children (18 and under), pregnant women, women trying for pregnancy, and Type 1 hypo unaware users.

What unique features does the Dexcom G6 offer?

The Dexcom G6 is highly water-resistant and allows users to share their glucose data in real-time with up to 10 followers using the 'Follow' app.

What is the significance of the Dexcom G6 integration with Omnipod® 5 in clinical trials?

The Dexcom G6 was exclusively used in clinical trials leading to the regulatory approval of Omnipod® 5 in Europe, Canada, and the United States, showcasing its effectiveness and reliability.